Business Context and Reporting Period
Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for tissue protection, healing, and repair. Key products include ORTHOVISC (osteoarthritis), AMVISC/AMVISC Plus (ophthalmic viscoelastic), HYVISC (equine osteoarthritis), and INCERT (anti-adhesive). The company relies heavily on strategic partnerships for distribution, including Johnson & Johnson (DePuy Mitek) for ORTHOVISC in the U.S., Bausch & Lomb for ophthalmic products, and Galderma for the upcoming cosmetic tissue augmentation product, ELEVESS.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Total Revenue | $26.84 million | $29.83 million |
| Product Revenue | $23.95 million | $20.53 million |
| Licensing/Contract Revenue | $2.89 million | $9.30 million |
| Net Income | $4.60 million | $5.89 million |
| Diluted EPS | $0.41 | $0.52 |
| Product Gross Margin | 54% | 46% |
| Cash and Cash Equivalents | $47.17 million | $44.75 million |
| Working Capital | $52.15 million | $46.58 million |
| Operating Cash Flow | $2.00 million | $6.45 million |
Note: The filing does not disclose long-term debt as of December 31, 2006. The company plans to utilize debt financing for a new facility in 2007.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 10% to $26.84 million. This was primarily driven by a significant drop in licensing and contract revenue ($6.5 million decrease) due to the absence of the OrthoNeutrogena termination fee and reimbursement costs recognized in 2005.
- Product Revenue Growth: Product revenue increased 17% to $23.95 million. This was led by a 43% surge in ORTHOVISC sales, driven by resumed shipments to DePuy Mitek (after a 2005 inventory overstock) and increased royalties. Ophthalmic product sales grew 2%.
- International Headwinds: International ORTHOVISC sales declined 3% due to the Turkish government eliminating reimbursement for the product in Q3 2006, resulting in zero shipments to Turkey for the last five months of the year.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 23% to $6.68 million, largely due to the adoption of SFAS 123R, which added $1.27 million in stock-based compensation expense. Research and development (R&D) expenses decreased 24% to $3.62 million due to reduced clinical trial spending compared to the pivotal trial costs in 2005.
- Margin Expansion: Product gross margin improved from 46% to 54%, attributed to higher royalty revenue, favorable raw material prices, and the absence of the 2005 voluntary product recall costs.
Guidance, Outlook, and Risks
- New Facility: The company entered a lease in January 2007 for a new 134,000 sq. ft. facility in Bedford, MA. The buildout is expected to cost approximately $25 million, with 60% financed via long-term debt. Occupancy is expected to begin in late 2007/2008.
- Product Launches: The company received FDA approval for its initial cosmetic tissue augmentation (CTA) product in December 2006. An enhanced version, ELEVESS, is expected to launch globally in mid-2007 in partnership with Galderma.
- Reimbursement Improvements: In December 2006, the Centers for Medicare and Medicaid Services (CMS) assigned a unique reimbursement code (Q-code) to ORTHOVISC, effective January 1, 2007. Management expects this to significantly boost U.S. sales in 2007.
- Key Risks:
- Customer Concentration: Three customers accounted for 79% of product revenue in 2006. Bausch & Lomb and DePuy Mitek are critical partners.
- Regulatory Dependence: Future success depends on FDA and foreign regulatory approvals for new products and the maintenance of existing approvals.
- Financing: The company intends to secure debt financing for the new facility; failure to obtain favorable terms could impact operations.
- International Sales: Continued uncertainty regarding the resumption of sales in Turkey and other international markets.
Investor Verification Checklist
- Debt Financing Status: Verify if the company has secured the long-term debt financing required for the $25 million Bedford facility buildout.
- ORTHOVISC U.S. Sales Trajectory: Monitor Q1 and Q2 2007 sales data to confirm the anticipated impact of the new CMS reimbursement code.
- ELEVESS Launch Timeline: Confirm the mid-2007 commercial launch date for the enhanced CTA product with Galderma and initial sales performance.
- Turkey Market Recovery: Assess whether sales to the Turkish distributor have resumed and at what volume compared to 2006.
- Inventory Levels: Review inventory balances to ensure the build-up related to the Turkey reimbursement issue has been resolved or is being managed effectively.